ORTHOFIX MEDICAL INC. Financials Orthofix Medical Inc.
Equities
OFIX
US68752M1080
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.99 USD | -0.84% |
|
-0.84% | -3.64% |
| Apr. 16 | Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer | CI |
| Apr. 12 | Orthofix Medical Inc. Announces Board Resignation | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 880 | 831 | 613.9 | 410.8 | 495.5 | 485.9 | - | - |
| Enterprise Value (EV) 1 | 880 | 831 | 613.9 | 410.8 | 495.5 | 485.9 | 485.9 | 485.9 |
| P/E ratio | -30.6 x | 331 x | -15.9 x | -20.9 x | -3.27 x | -8.81 x | -16 x | -111 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.91 x | 2.04 x | 1.32 x | 0.89 x | 0.66 x | 0.61 x | 0.57 x | 0.53 x |
| EV / Revenue | 1.91 x | 2.04 x | 1.32 x | 0.89 x | 0.66 x | 0.61 x | 0.57 x | 0.53 x |
| EV / EBITDA | 11.6 x | 17.4 x | 10 x | 8.46 x | 10.7 x | 7.58 x | 5.62 x | 4.28 x |
| EV / FCF | 67,502,839 x | 14,135,138 x | 889,681,758 x | - | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 19,055 | 19,334 | 19,745 | 20,008 | 36,757 | 37,407 | - | - |
| Reference price 2 | 46.18 | 42.98 | 31.09 | 20.53 | 13.48 | 12.99 | 12.99 | 12.99 |
| Announcement Date | 2/24/20 | 2/26/21 | 2/25/22 | 3/6/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 460 | 406.6 | 464.5 | 460.7 | 746.6 | 791 | 846.8 | 908.5 |
| EBITDA 1 | 75.72 | 47.63 | 61.26 | 48.55 | 46.28 | 64.07 | 86.53 | 113.5 |
| EBIT 1 | -18.78 | -6.266 | -8.315 | -13.27 | -139.1 | -49.84 | -33.64 | 6.267 |
| Operating Margin | -4.08% | -1.54% | -1.79% | -2.88% | -18.63% | -6.3% | -3.97% | 0.69% |
| Earnings before Tax (EBT) 1 | -27.05 | -0.368 | -13.5 | -17.71 | -148.7 | -64.2 | -38.31 | -10 |
| Net income 1 | -28.46 | 2.517 | -38.38 | -19.75 | -151.4 | -56.13 | -32.88 | -6.233 |
| Net margin | -6.19% | 0.62% | -8.26% | -4.29% | -20.28% | -7.1% | -3.88% | -0.69% |
| EPS 2 | -1.510 | 0.1300 | -1.950 | -0.9800 | -4.120 | -1.475 | -0.8100 | -0.1167 |
| Free Cash Flow | 13.04 | 58.79 | 0.69 | - | - | - | - | - |
| FCF margin | 2.83% | 14.46% | 0.15% | - | - | - | - | - |
| FCF Conversion (EBITDA) | 17.22% | 123.43% | 1.13% | - | - | - | - | - |
| FCF Conversion (Net income) | - | 2,335.6% | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/26/21 | 2/25/22 | 3/6/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 112.4 | 125.1 | 106.4 | 118.1 | 114 | 122.2 | 175.2 | 187 | 184 | 200.4 | 184.3 | 196.4 | 197.3 | 213.1 | 196.4 |
| EBITDA 1 | 11.88 | 17.01 | 7.109 | 11.42 | 14.26 | 15.77 | 3.204 | 9.919 | 13.52 | 19.64 | 9.433 | 14.53 | 17.3 | 22.77 | 16 |
| EBIT 1 | -0.313 | -9.353 | -3.078 | 6.641 | -5.787 | -11.04 | -59.71 | -36.63 | -24.45 | -18.32 | -18.25 | -13.49 | -11.5 | -6.578 | -11.52 |
| Operating Margin | -0.28% | -7.48% | -2.89% | 5.62% | -5.08% | -9.04% | -34.08% | -19.59% | -13.29% | -9.14% | -9.9% | -6.87% | -5.83% | -3.09% | -5.87% |
| Earnings before Tax (EBT) 1 | -2.535 | -9.605 | -4.389 | 3.042 | -9.372 | -6.987 | -60.33 | -37.92 | -28.38 | -22.05 | -21.85 | -17.06 | -15.1 | -10.16 | -14.73 |
| Net income 1 | -2.171 | -32.81 | -4.46 | 2.489 | -10.72 | -7.062 | -60.94 | -39.43 | -28.86 | -22.17 | -19.19 | -14.96 | -13.16 | -8.84 | -11.46 |
| Net margin | -1.93% | -26.24% | -4.19% | 2.11% | -9.4% | -5.78% | -34.78% | -21.08% | -15.68% | -11.06% | -10.41% | -7.62% | -6.67% | -4.15% | -5.84% |
| EPS 2 | -0.1100 | -1.650 | -0.2200 | 0.1200 | -0.5300 | -0.3500 | -1.710 | -1.070 | -0.7700 | -0.5900 | -0.5125 | -0.3950 | -0.3450 | -0.2250 | -0.2950 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 2/25/22 | 5/6/22 | 8/5/22 | 11/3/22 | 3/6/23 | 5/9/23 | 8/8/23 | 11/8/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 13 | 58.8 | 0.69 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -8.69% | 0.74% | -11.1% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -5.74% | 0.49% | 3.42% | - | - | - | - | - |
| Assets 1 | 495.6 | 510.8 | -1,121 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 19 | 15.5 | 17.8 | 21.4 | 60.3 | 10 | 10 | - |
| Capex / Sales | 4.13% | 3.81% | 3.83% | 4.64% | 8.07% | 1.26% | 1.18% | - |
| Announcement Date | 2/24/20 | 2/26/21 | 2/25/22 | 3/6/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
12.99
USD
Average target price
18.47
USD
Spread / Average Target
+42.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.64% | 486M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- OFIX Stock
- Financials Orthofix Medical Inc.
